Alkynyl aryl carboxamides

1. A method of treating at least one disease, in a mammal in need thereof, wherein the at least one disease is selected from the group consisting of diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholerstrolemia, obesity, and polycystic ovary syndrome, comprising

administering at least one alkynyl aryl carboxamide of Formula (I′)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is a C 2 -C 15 alkynyl, or C 2 -C 6 -alkynyl aryl;

Cy is an aryl;

Cy′ is an aryl, which may optionally be fused by a 3-8 membered cycloalkyl;

n is 0 or 1;

R 1 and R 2 are independently from each other selected from the group consisting of hydrogen and C 1 -C 6 -alkyl;

R 3 is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl amine, C 1 -C 6 -alkyl alkoxy, C 1 -C 6 -alkyl carboxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl; C 2 -C 6 -alkynyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl cycloalkyl, C 2 -C 6 -alkenyl heterocycloalkyl, C 2 -C 6 -alkynyl cycloalkyl, and C 2 -C 6 -alkynyl heterocycloalkyl;

R 4 and R 5 are independently from each other selected from the group consisting of H, hydroxy, fluoro, C 1 -C 6 alkyl, carboxy, C 1 -C 6 alkoxy, C 1 -C 3 alkyl carboxy, C 2 -C 3 alkenyl carboxy, and C 2 -C 3 alkynyl carboxy, wherein at least one of R 4 or R 5 is neither a hydrogen nor a C 1 -C 6 alkyl; to the mammal in an amount sufficient to treat or prevent the at least one disease.

2. A method of treating at least one disease in a mammal in need thereof, wherein the at least one disease is selected from the group consisting of diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholerstrolemia, obesity, and polycystic ovary syndrome, comprising

administering at least one alkynyl aryl carboxamide of Formula (I)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is a C 2 -C 15 alkynyl, or C 2 -C 6 -alkynyl aryl;

Cy is an aryl;

n is 0 or 1;

R 1 and R 2 are independently from each other selected from the group consisting of hydrogen and C 1 -C 6 -alkyl;

R 3 is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl amine, C 1 -C 6 -alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8 membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl cycloalkyl, C 2 -C 6 -alkenyl heterocycloalkyl, C 2 -C 6 -alkynyl cycloalkyl, and C 2 -C 6 -alkynyl heterocycloalkyl;

R 4 and R 5 are each independently from each other selected from the group consisting of H, hydroxy, C 1 -C 6 alkyl, carboxy, C 1 -C 6 alkoxy, C 1 -C 3 alkyl carboxy, C 2 -C 3 alkenyl carboxy, C 2 -C 3 alkynyl carboxy, and amino, or R 4 and R 5 may form an unsaturated or saturated heterocyclic ring, wherein at least one of R 4 or R 5 is not a hydrogen or C 1 -C 6 alkyl; to the mammal in an amount sufficient to treat or prevent the at least one disease.

3. A method of treating at least one disease in a mammal in need thereof, wherein the at least one disease is selected from the group consisting of metabolic disorders mediated by insulin resistance or hyperglycemia, inflammatory diseases, and combinations thereof, comprising

administering at least one alkynyl aryl carboxamide of Formula (I′)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is a C 2 -C 15 alkynyl, or C 2 -C 6 -alkynyl aryl;

Cy is an aryl;

Cy′ is an aryl, which may optionally be fused by a 3-8 membered cycloalkyl;

n is 0 on;

R 1 and R 2 are independently from each other selected from the group consisting of hydrogen and C 1 -C 6 -alkyl;

R 3 is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl amine, C 1 -C 6 -alkyl alkoxy, C 1 -C 6 -alkyl carboxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl; C 2 -C 6 -alkynyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl cycloalkyl, C 2 -C 6 -alkenyl heterocycloalkyl, C 2 -C 6 -alkynyl cycloalkyl, and C 2 -C 6 -alkynyl heterocycloalkyl;

R 4 and R 5 are independently from each other selected from the group consisting of H, hydroxy, fluoro, C 1 -C 6 alkyl, carboxy, C 1 -C 6 alkoxy, C 1 -C 3 alkyl carboxy, C 2 -C 3 alkenyl carboxy, and C 2 -C 3 alkynyl carboxy, wherein at least one of R 4 or R 5 is neither a hydrogen nor a C 1 -C 6 alkyl; to the mammal in an amount sufficient to treat or prevent the at least one disease.

4. The method of claim 1 , wherein the method is a method of treating.

5. The method of claim 2 , wherein the method is a method of treating.

6. The method of claim 3 , wherein the method is a method of treating.

7. The method of claim 1 , wherein R 1 and R 2 are each H.

8. The method of claim 1 , wherein Cy is a phenyl group.

9. The method of claim 1 , wherein A is a moiety of the formula —C≡C—R 6 , and wherein R 6 is C 6 -C 12 alkyl, a 3-8 membered cycloalkyl, C 1 -C 6 alkyl-(3-8 membered) cycloalkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, phenyl, C 1 -C 12 alkyl phenyl, C 2 -C 6 -alkenyl phenyl, or a C 2 -C 6 -alkynyl phenyl.

10. An alkynyl aryl carboxamide or its salt according to any of formulae (Ia), (Ib), (Ic) or (It):

wherein

A is a C 2 -C 15 alkynyl, or C 2 -C 6 -alkynyl aryl;

Cy is an aryl;

n is 0 or 1;

R 1 and R 2 are independently from each other is selected from the group consisting of hydrogen and C 1 -C 6 -alkyl; and wherein

R 3 is selected from the group consisting of H, hydroxy, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl amine, C 1 -C 6 -alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl cycloalkyl, C 2 -C 6 -alkenyl heterocycloalkyl, C 2 -C 6 -alkynyl cycloalkyl, and C 2 -C 6 -alkynyl heterocycloalkyl.

11. An alkynyl aryl carboxamide or its salt according to claim 10 having the formula (Ib)

wherein

A is a C 2 -C 15 alkynyl, or C 2 -C 6 -alkynyl;

Cy is an aryl;

n is 0 or 1;

R 1 and R 2 are independently from each other is selected from the group consisting of hydrogen and C 1 -C 6 -alkyl; and wherein

R 3 is selected from the group consisting of H, hydroxy, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl amine, C 1 -C 6 -alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl cycloalkyl, C 2 -C 6 -alkenyl heterocycloalkyl, C 2 -C 6 -alkynyl cycloalkyl, and C 2 -C 6 -alkynyl heterocycloalkyl.

12. An alkynyl aryl carboxamide or its salt according to any of formulae (Id) or (Ie):

wherein

A is a C 2 -C 15 alkynyl, or C 2 -C 6 -alkynyl aryl;

Cy is an aryl;

n is 0 or 1;

R 1 and R 2 are independently from each other is selected from the group consisting of hydrogen and C 1 -C 6 -alkyl;

R 3 is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl amine, C 1 -C 6 -alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8 membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl cycloalkyl, C 2 -C 6 -alkenyl heterocycloalkyl, C 2 -C 6 -alkynyl cycloalkyl, and C 2 -C 6 -alkynyl heterocycloalkyl.

13. The alkynyl aryl carboxamide or its salt of claim 10 , wherein R 1 and R 2 are each H, Cy is a phenyl group, and A is a moiety of the formula —C≡C— R 6 ; wherein R 6 is C 6 -C 12 alkyl, a 3-8 membered cycloalkyl, C 1 -C 6 alkyl-(3-8 membered) cycloalkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, phenyl, C 1 -C 12 alkyl phenyl, C 2 -C 6 -alkenyl phenyl, or C 2 -C 6 -alkynyl phenyl.

14. The alkynyl aryl carboxamide or its salt claim 10 , selected from the group consisting of:

5-[(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]-2-hydroxybenzoic acid;

5-[(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid;

5-[(4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-[Acetyl(4-dec-1-ynylbenzyl)amino]-2-hydroxybenzoic acid;

5-[(4-Dec-1-ynylbenzyl)(pyridin-3-ylcarbonyl)amino]-2-hydroxybenzoic acid;

5-[(4-Dec-1-ynylbenzyl)(isonicotinoyl)amino]-2-hydroxybenzoic acid;

5-((4-Dec-1-ynylbenzyl)[(2E)-3-phenylprop-2-enoyl]amino)-2-hydroxybenzoic acid;

5-[(4-Dec-1-ynylbenzyl)(thien-2-ylacetyl)amino]-2-hydroxybenzoic acid;

5-((4-Dec-1-ynylbenzyl){(2E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl}amino)-2-hydroxybenzoic acid;

5-[(4-Dec-1-ynylbenzyl)(phenoxyacetyl)amino]-2-hydroxybenzoic acid;

[4-({(4-Dec-1-ynylbenzyl)[(2E)-3-phenylprop-2-enoyl]amino)methyl)phenoxy]acetic acid;

(4-{[(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]methyl)phenoxy)acetic acid;

(4-{[(4-Dec-1-ynylbenzyl)(hexanoyl)amino]methyl}phenoxy)acetic acid;

(4-{[Acetyl(4-dec-1-ynylbenzyl)amino]methyl}phenoxy)acetic acid;

2-(Carboxymethoxy)-5-({(4-dec-1-ynylbenzyl) [(2E)-3-phenylprop-2-enoyl]amino)methyl)benzoic acid;

2-(Carboxymethoxy)-5-{[(3-cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]methyl}benzoic acid;

5-{[Acetyl(4-dec-1-ynylbenzyl)amino]methyl)-2-(carboxymethoxy)benzoic acid (2E)-3-(4-{[(4-Dec-1-ynylbenzyl)(3-phenylpropanoyl)amino]methyl)phenyl)acrylic acid;

(2E)-3-(4-[(4-Dec-1-ynylbenzyl)(3-phenylpropanoyl)amino]phenyl}acrylic acid;

(2E)-3-{4-[Acetyl(4-dec-1-ynylbenzyl)amino]phenyl}acrylic acid;

3-(4-{[(3-Cyclopentylpropanoyl)(4-dec-ynylbenzyl)amino]methyl}phenyl)propanoic acid;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl)(cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(hexanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-((4-tert-Butylbenzoyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-((Biphenyl-4-ylcarbonyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3,3-dimethylbutanoyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(2,3-dihydro-1-benzofuran-5-ylcarbonyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl)(7-carboxyheptanoyl)amino]-2-hydroxybenzoic acid;

5-((1,3-Benzodioxol-5-ylcarbonyl) {4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl)(2,2-dimethylpropanoyl)amino]-2-hydroxybenzoic acid;

5-([(Benzyloxy)acetyl]{4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(4-hexylbenzoyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl)(2-naphthoyl)amino]-2-hydroxybenzoic acid;

5-((1-Benzothien-2-ylcarbonyl) {4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-{[{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]methyl}-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-{[{4-[(4-Butylphenyl)ethynyl]benzyl}(hexanoyl)amino]methyl)-2-hydroxybenzoic acid;

(4-{[{4-[(4-Butylphenyl)ethynyl]benzyl}(hexanoyl)amino]methyl)phenoxy)acetic acid, N-methyl-D-glucamine;

(4-{[{4-[(4-Butylphenyl)ethynyl]benzyl}(cyanoacetyl)amino]methyl)phenoxy)acetic acid;

(4-{[{4-[(4-Butylphenyl)ethynyl]benzyl)(1H-indazol-3-ylcarbonyl)amino]methyl}-phenoxy)acetic acid;

(4-{[{4-[(4-Butylphenyl)ethynyl]benzyl)(pent-4-ynoyl)amino]methyl}phenoxy)-acetic acid;

[4-({4-[(4-Butylphenyl)ethynyl]benzyl}[(6-hydroxypyridin-3-yl)carbonyl]amino)-methyl-phenoxy]acetic acid;

[4-({{4-[(4-Butylphenyl)ethynyl]benzyl}[(2-methoxyethoxy)acetyl]amino}methyl)-phenoxy]acetic acid;

(4-{[{4-[(4-Butylphenyl)ethynyl]benzyl)(1H-pyrazol-4-ylcarbonyl)amino]-methyl)phenoxy)acetic acid 3-[(3-Cyclopentylpropanoyl)(4-dec-1-yn-1-ylbenzyl)amino]benzoic acid, N-methyl-D-glucamine;

3-[(4-Dec-1-yn-1-ylbenzyl)(hexanoyl)amino]benzoic acid;

4-{[{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]methyl)-benzoic acid;

4-{[{4-[(4-Butylphenyl)ethynyl]benzyl)(hexanoyl)amino]methyl}benzoic acid;

4-[((4-tert-Butylbenzoyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)methyl]benzoic acid;

4-[{4-[(4-Butylphenyl)ethynyl]benzyl)(hexanoyl)amino]benzoic acid;

4-[{4-[(4-Butylphenyl)ethynyl]benzyl)(3-cyclopentylpropanoyl)amino]benzoic acid;

8-[{4-[(4-Butylphenyl)ethynyl]benzyl)(3-cyclopentylpropanoyl)amino]-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid, N-methyl-D-glucamine;

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-[f4-[(4-Chlorophenyl)ethynyl]benzyl}(4-heptylbenzoyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(isoxazol-5-ylcarbonyl)amino]-2-hydroxy-benzoic acid;

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(2-thienylacetyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(3-phenylpropanoyl)amino]-2-hydroxy-benzoic acid, N-methyl-D-glucamine;

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(4-methoxybenzoyl)amino]-2-hydroxy-benzoic acid, N-methyl-D-glucamine;

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(3-fluorobenzoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-(acetyl {4-[(4-Chlorophenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-[{4-[(4-Butylphenyl)ethynyl]-2-fluorobenzyl)(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

8-((3-Cyclopentylpropanoyl) {4-[(4-fluorophenyl)ethynyl]benzyl}amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid, N-methyl-D-glucamine;

5-[f4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl)(3,3-dimethylbutanoyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine;

5-[{4-[(4-Butylphenyl)ethynyl]benzyl)(2-thienylacetyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine;

4-[{4-[(4-Butylphenyl)ethynyl]benzyl)(3,3-dimethylbutanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

3-[{4-[(4-Butylphenyl)ethynyl]benzyl)(3-cyclopentylpropanoyl)amino]-4-fluorobenzoic acid;

4-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-(Acetyl{4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-[{4-[(4-Butylphenyl)ethynyl]benzyl}(cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-[{4-[(4-Butylphenyl)ethynyl]benzyl)(hexanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-[{4-[(4-Butylphenyl)ethynyl]benzyl)(3-cyclopentylpropanoyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine;

4-[{4-[(4-Butylphenyl)ethynyl]benzyl)(2,2-dimethylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-((3-Cyclopentylpropanoyl)(4-[(4-methoxyphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-[{4-[(4-tert-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-((3-Cyclopentylpropanoyl) {4-[(4-propoxyphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine

4-((3-Cyclopentylpropanoyl) {4-[(4-propylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine, and

4-{(3-Cyclopentylpropanoyl)[4-(5-phenylpent-1-yn-1-yl)benzyl]amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine.

15. A composition comprising at least one alkynyl aryl carboxamide of claim 10 or its salt and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

16. A pharmaceutical composition comprising at least one alkynyl aryl carboxamide of claim 11 or its salt and a pharmaceutically acceptable carrier, diluent excipient, or combination thereof.

17. The pharmaceutical composition of claim 16 , further comprising at least one supplementary drug selected from the group consisting of insulin, aldose reductase inhibitors, alpha-glucosidase inhibitors, sulfonyl urea agents, biguanides thiazolidindiones, PPARs agonists, c-Jun Kinase and GSK-3 inhibitors.

18. The pharmaceutical composition of claim 17 wherein the at least one supplementary drug is selected from the group consisting of a rapid acting insulin, an intermediate acting insulin, a long acting insulin, a combination of intermediate and rapid acting insulins, Minalrestat, Tolrestat, Sorbinil, Methosorbinil, Zopolrestat, Epalrestat, Zenarestat, Imirestat, Ponalrestat, ONO-2235, GP-1447, CT-112, BAL-ARI 8, AD-5467, ZD5522, M-16209, NZ-314, M-79175, SPR-210, ADN 138, SNK-860, Miglitol, Acarbose, Glipizide, Glyburide, Chiorpropamide, Tolbutamide, Tolazamide, and Glimepriride.

19. A method of preparing the alkynyl aryl carboxamide of claim 10 , comprising deprotecting, transforming, or deprotecting and transforming the compound of formula (Z) to form the alkynyl aryl carboxamide of formula (I)

wherein FG is A or a leaving group.

20. The method of claim 2 , wherein R 1 and R 2 are each H.

21. The method of claim 3 , wherein R 1 and R 2 are each H.

22. The method of claim 2 , wherein Cy is a phenyl group.

23. The method of claim 3 , wherein Cy is a phenyl group.

24. The method of claim 2 , wherein A is a moiety of the formula —C≡C—R 6 , and wherein R 6 is C 6 -C 2 alkyl, a 3-8 membered cycloalkyl, C 1 -C 6 alkyl-(3-8 membered) cycloalkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, phenyl, C 1 -C 12 alkyl phenyl, C 2 -C 6 -alkenyl phenyl, or a C 2 -C 6 -alkynyl phenyl.

25. The method of claim 3 , wherein A is a moiety of the formula —C≡C—R 6 , and wherein R 6 is C 6 -C 12 alkyl, a 3-8 membered cycloalkyl, C 1 -C 6 alkyl-(3-8 membered) cycloalkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, phenyl, C 1 -C 12 alkyl phenyl, C 2 -C 6 -alkenyl phenyl, or a C 2 -C 6 -alkynyl phenyl.